---
title: "Weekly Recap | Abcellera Biologics -4.72%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298798795.md"
description: "Abcellera Biologics (ABCL) fell 4.72% this week to $10.89, underperforming the S&P 500 by about 3.92 percentage points. The stock had a wide 11.69% trading range. It opened Tuesday at $11.29 and pushed up to $11.64 before fading, hit a Thursday low of $10.32, then stabilised at $10.89 on Friday. The price action was a sharp rise followed by a pullback, with no major company-specific catalyst."
datetime: "2026-09-12T07:38:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298798795.md)
  - [en](https://longbridge.com/en/news/298798795.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298798795.md)
generator: "portal-rs"
---

# Weekly Recap | Abcellera Biologics -4.72%, consensus target above spot

## The Week

Abcellera Biologics (ABCL) fell 4.72% this week to $10.89, underperforming the S&P 500 by about 3.92 percentage points. The stock had a wide 11.69% trading range. It opened Tuesday at $11.29 and pushed up to $11.64 before fading, hit a Thursday low of $10.32, then stabilised at $10.89 on Friday. The price action was a sharp rise followed by a pullback, with no major company-specific catalyst.

## Analyst Ratings

Out of 9 brokers covering the stock, 8 rate it buy and 1 rates it outperform, with no hold or sell ratings. The consensus rating is strong buy, with a consensus target of $17.125, about 57.25% above the current price. Target prices range from $9.00 to $30.00, showing wide dispersion. ABCL ranks 24th among 54 companies in the life science tools and services industry.

## The Week Ahead

Next week brings a busy macro calendar. Tuesday features the New York Fed manufacturing index, with a prior reading of 20.6 and a forecast of 14.75. Wednesday brings retail sales, retail sales ex-autos, import prices, the NAHB housing market index, and EIA crude inventories. There are no major company-specific events scheduled.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ABCL.US](https://longbridge.com/en/quote/ABCL.US.md)

## Related News & Research

- [AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 | ABCL Stock News](https://longbridge.com/en/news/299230195.md)
- [Jones Trading maintains Buy rating on Adamas Trust, $10 price target](https://longbridge.com/en/news/299341318.md)
- [Thelen unit Lamparter builds steel arch façades for Stuttgart main station project](https://longbridge.com/en/news/299334128.md)
- [Bitcoin Core 32.0 targets speed and security fixes ahead of October 10 release](https://longbridge.com/en/news/299224082.md)
- [MBody AI Completes Name Change Following Merger and $10 Million Offering | MBAI Stock News](https://longbridge.com/en/news/299185311.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**